517918-95-5

Basic information

• Product Name: 1H-PYRROLO[2,3-B]PYRIDINE-5-CARBONITRILE
• Synonyms: 1H-PYRROLO[2,3-B]PYRIDINE-5-CARBONITRILE;5-CYANO-7-AZAINDOLE;1H-Pyrrolo[2,3-b]pyridine-5-carbonitrile(9CI);5-canyo-1H-Pyrrolo[2,3-b]pyridine;7-Azaindole-5-carbonitrile;7-Azaindole-5-carbonitrile,1H-Pyrrolo[2,3-b]pyridine-5-carbonitrile;5-Cyano-1H-pyrrolo[2,3-b]pyridine
• CAS NO: 517918-95-5
• Molecular Formula: C₈H₅N₃
• Molecular Weight: 143.15
• EINECS: 1806241-263-5
• Product Categories: PYRIDINE;Boron, Nitrile, Thio,& TM-Cpds;Heterocycles;Heterocycle-Pyridine series
• Mol File: 517918-95-5.mol

Chemical Properties

• Melting Point: 225.1-225.2°C
• Appearance: /
• Density: 1.34 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 12.50±0.40(Predicted)
• CAS DataBase Reference: 1H-PYRROLO[2,3-B]PYRIDINE-5-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-PYRROLO[2,3-B]PYRIDINE-5-CARBONITRILE(517918-95-5)
• EPA Substance Registry System: 1H-PYRROLO[2,3-B]PYRIDINE-5-CARBONITRILE(517918-95-5)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-36/37/38
• Safety Statements: 26-36/37
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 517918-95-5(Hazardous Substances Data)

Usage

Chemical Properties

Yellow fine crystalline powder

Upstream product

• 557-21-1 zinc(II) cyanide 
• 183208-35-7 5-bromo-1H-pyrrolo[2,3-b]pyridine 
• 143-33-9 sodium cyanide 
• 557-21-1 dicyanozinc 

Downstream Products

• 864681-18-5 1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid ethyl ester 
• 1244037-18-0 propane-1-sulfonic acid {3-[(5-cyano-1H-pyrrolo[2,3-b]pyridin-3-yl)-hydroxy-methyl]-2,4-difluoro-phenyl}-amide 
• 1244037-20-4 propane-1-sulfonic acid {3-[(5-cyano-1H-pyrrolo[2,3-b]pyridin-3-yl)-hydroxy-methyl]-2-fluoro-phenyl}-amide 
• 1244037-26-0 {3-[(5-cyano-1H-pyrrolo[2,3-b]pyridin-3-yl)-hydroxy-methyl]-2,4-difluorophenyl}-carbamic acid benzyl ester 
• 1201323-97-8 5-Fluoro-2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-oxazolo[5,4-b]pyridine 
• 934568-20-4 1-methyl-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid 
• 1201324-19-7 C₉H₇ClN₂O 
• 849067-96-5 1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methyl ester 
• 1060816-80-9 3-iodo-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid 
• 757978-12-4 3-iodo-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile 

Relevant articles and documents

HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME

A heterocyclic compound represented by formula XI, a pharmaceutically acceptable salt, a solvate, or a solvate of a pharmaceutically acceptable salt thereof, use thereof, and a composition containing the same. The compound is novel in structure and has good STAT5 inhibitory activity.

Selective inhibition of Helicobacter pylori methionine aminopeptidase by azaindole hydroxamic acid derivatives: Design, synthesis, in vitro biochemical and structural studies

Methionine aminopeptidases (MetAPs) are an important class of enzymes that work co-translationally for the removal of initiator methionine. Chemical inhibition or gene knockdown is lethal to the microbes suggesting that they can be used as antibiotic targ

Indole-like derivatives and application thereof

The invention relates to indole-like derivatives and application thereof. The compounds have a structure as shown in a formula I. The compounds have ROR [gamma] t regulating activity and are expected to be used for preparing medicines for preventing and treating diseases related to ROR [gamma] t.

DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES

The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.

GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a novel compound having GPR40 receptor agonist activity that promotes insulin secretion and inhibits blood sugar rise after glucose loading, and is thereby useful for the treatment of diabetes and complications thereof, the preparation method thereof and pharmaceutical composition containing them as an active ingredient.

NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7

The present invention relates to imidazolone derivatives of formula (I) to methods of preparing such derivatives, intermediates thereto, pharmaceutical compositions comprising such derivatives, and methods of inhibiting protein kinase, and methods of treatment comprising administration of such derivatives.

NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND

Disclosed is an antimalarial agent containing a compound represented by the formula: [wherein A1 represents a 3-pyridyl group that may have a substituent, a 6-quinolyl group that may have a substituent, or the like; X1 represents a group represented by the formula -C(=O)-NH- or the like; E represents a furyl group, a thienyl group or a phenyl group; with the proviso that A1 may have one to three substituents, and E has one of two substituents] or a salt thereof or hydrates thereof.

Compounds and methods for development of Ret modulators

Compounds active on Ret are described, as well as methods of using such compounds. Also described are crystal structures of Ret surrogates that were determined using X-ray crystallography. The use of such Ret surrogate crystals and strucural information can, for example, be used for identifying molecular scaffolds and for developing ligands that bind to and modulate Ret and for identifying improved ligands based on known ligands.

NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND

The present invention provides an antifungal agent represented by the formula: [wherein A1 represents a 3-pyridyl group which may have a substituent, a quinolyl group which may have a substituent, or the like; X1 represents a group represented by the formula -NH-C(=O)-, a group represented by the formula -C(=O)-NH-, or the like; E represents a furyl group, a thienyl group, a pyrrolyl group, a phenyl group, a pyridyl group, a tetrazolyl group, a thiazolyl group or a pyrazolyl group; with the proviso that A1 may have 1 to 3 substituents, and E has one or two substituents].

3,5-DISUBSTITUTED 1H-PZRROLO [2,3-B] PYRIDINES AS JNK INHIBITORS

The present invention provides novel compounds of formula (I) and their use in the inhibition of c-Jun N-terminal kinases. The present invention further provides the use of these compounds in medicine, in particular in the prevention and/or treatment of n